1. A rare case of primary choriocarcinoma in the sigmoid colon.
- Author
-
Maehira H, Shimizu T, Sonoda H, Mekata E, Yamaguchi T, Miyake T, Ishida M, and Tani T
- Subjects
- Adenocarcinoma complications, Adenocarcinoma secondary, Adenocarcinoma therapy, Aged, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bevacizumab, Biopsy, Chemotherapy, Adjuvant, Choriocarcinoma, Non-gestational complications, Choriocarcinoma, Non-gestational secondary, Choriocarcinoma, Non-gestational therapy, Colectomy, Colonoscopy, Disease Progression, Drug Screening Assays, Antitumor, Fatal Outcome, Humans, Liver Neoplasms secondary, Male, Melena etiology, Neoplasms, Complex and Mixed complications, Neoplasms, Complex and Mixed secondary, Neoplasms, Complex and Mixed therapy, Sigmoid Neoplasms complications, Sigmoid Neoplasms therapy, Time Factors, Tomography, X-Ray Computed, Treatment Outcome, Adenocarcinoma pathology, Choriocarcinoma, Non-gestational pathology, Neoplasms, Complex and Mixed pathology, Sigmoid Neoplasms pathology
- Abstract
Primary colorectal choriocarcinoma is an extremely rare neoplasm and is usually associated with a poor prognosis. Only 13 cases of colorectal choriocarcinoma have previously been reported. There is no standard chemotherapeutic regimen for this tumor type. A 68-year-old man presented with melena and was diagnosed with sigmoid colonic adenocarcinoma with multiple liver metastases. He underwent a laparoscopic sigmoidectomy. Pathology revealed choriocarcinoma with a focal component of moderately differentiated adenocarcinoma of colon origin. Based on the collagen gel droplet-embedded culture drug sensitivity test (CD-DST) results, mFOLFOX6 and bevacizumab were administered, which suppressed aggressive tumor growth for 4 mo. The patient died 9 mo after the initial diagnosis. Our study results suggest that the standard chemotherapy regimen for colorectal cancer might have suppressive effects against primary colorectal choriocarcinoma. Moreover, CD-DST may provide, at least in part, therapeutic insight for the selection of appropriate antitumor agents for such patients.
- Published
- 2013
- Full Text
- View/download PDF